Clinical Research Directory
Browse clinical research sites, groups, and studies.
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
Sponsor: AstraZeneca
Summary
To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing setting.
Official title: Specific Use-results Study of IMFINZI Intravenous Infusion 120 mg,500mg in Patients With Curatively Unresectable Biliary Tract Cancer
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
236
Start Date
2023-06-06
Completion Date
2025-11-21
Last Updated
2026-09-24
Healthy Volunteers
No
Conditions
Locations (24)
Research Site
Aichi, Japan
Research Site
Aomori, Japan
Research Site
Chiba, Japan
Research Site
Ehime, Japan
Research Site
Fukushima, Japan
Research Site
Hokkaido, Japan
Research Site
Hyōgo, Japan
Research Site
Kagawa, Japan
Research Site
Kanagawa, Japan
Research Site
Kyoto, Japan
Research Site
Miyagi, Japan
Research Site
Nagano, Japan
Research Site
Nagasaki, Japan
Research Site
Nara, Japan
Research Site
Numakunai, Japan
Research Site
Okayama, Japan
Research Site
Osaka, Japan
Research Site
Saitama, Japan
Research Site
Shiga, Japan
Research Site
Shimane, Japan
Research Site
Shizuoka, Japan
Research Site
Tochigi, Japan
Research Site
Tokyo, Japan
Research Site
Yamaguchi, Japan